Financial
FY2026 revenue €23.60bn; adjusted EBIT margin 16.2%.
Comparable revenue growth 4.0%; adjusted EBIT about €3.8bn. Net income not captured.
HQ Germany · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
FY2026 revenue €23.60bn; adjusted EBIT margin 16.2%.
Comparable revenue growth 4.0%; adjusted EBIT about €3.8bn. Net income not captured.
Source: official results release · Year ended 2026-09-30 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2026 | €23.6bn | — | — | — | Siemens Healthineers |
Products not yet catalogued.
FY2026 revenue €23.60bn; adjusted EBIT margin 16.2%.
Comparable revenue growth 4.0%; adjusted EBIT about €3.8bn. Net income not captured.
Nov 2025: Siemens AG decided to give up control of Siemens Healthineers, planning to spin off about 30% of the shares to its own shareholders and reduce its remaining ~67% stake to a financial investment over time, subject to approvals.
No data breaches, cyber incidents or regulator actions involving Siemens Healthineers found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Sep 2026: Siemens began an FDA Class 2 recall of ACUSON Origin ultrasound systems (software 4.0) because a software issue could unintentionally activate an uncleared Color Doppler setting and cause the system to crash or freeze.
No contract disputes, terminations or troubled implementations involving Siemens Healthineers found in HSH's search of the last 24 months.
No competitors linked yet.